PL1884775T3 - Sposób rozpoznawania chorób związanych z przeciwciałem przeciwko receptorowi AT 1 - Google Patents

Sposób rozpoznawania chorób związanych z przeciwciałem przeciwko receptorowi AT 1

Info

Publication number
PL1884775T3
PL1884775T3 PL06016296T PL06016296T PL1884775T3 PL 1884775 T3 PL1884775 T3 PL 1884775T3 PL 06016296 T PL06016296 T PL 06016296T PL 06016296 T PL06016296 T PL 06016296T PL 1884775 T3 PL1884775 T3 PL 1884775T3
Authority
PL
Poland
Prior art keywords
receptor antibody
diagnosis
receptor
disease involving
disease
Prior art date
Application number
PL06016296T
Other languages
English (en)
Polish (pl)
Inventor
Kai Schulze-Forster
Harald Heidecke
Original Assignee
Celltrend Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrend Gmbh filed Critical Celltrend Gmbh
Publication of PL1884775T3 publication Critical patent/PL1884775T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL06016296T 2006-08-04 2006-08-04 Sposób rozpoznawania chorób związanych z przeciwciałem przeciwko receptorowi AT 1 PL1884775T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06016296A EP1884775B1 (de) 2006-08-04 2006-08-04 Verfahren zur Diagnose einer Erkrankung mit Beteiligung eines Anti-AT1-Rezeptor-Antikörpers

Publications (1)

Publication Number Publication Date
PL1884775T3 true PL1884775T3 (pl) 2010-06-30

Family

ID=37401029

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06016296T PL1884775T3 (pl) 2006-08-04 2006-08-04 Sposób rozpoznawania chorób związanych z przeciwciałem przeciwko receptorowi AT 1
PL07802440T PL2057467T3 (pl) 2006-08-04 2007-07-31 Sposób diagnozowania choroby z udziałem przeciwciała przeciwko receptorowi AT1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07802440T PL2057467T3 (pl) 2006-08-04 2007-07-31 Sposób diagnozowania choroby z udziałem przeciwciała przeciwko receptorowi AT1

Country Status (7)

Country Link
US (1) US8425877B2 (de)
EP (2) EP1884775B1 (de)
AT (2) ATE454630T1 (de)
DE (1) DE602006011602D1 (de)
ES (2) ES2336350T3 (de)
PL (2) PL1884775T3 (de)
WO (1) WO2008015218A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123929A1 (de) 2001-05-11 2002-11-21 Celltrend Gmbh Verfahren zur Vorhersage eines Transplantatabstoßungsrisikos und immunologischer Testkit
EP1884776A1 (de) * 2006-08-04 2008-02-06 Celltrend GmbH Verfahren zur diagnose einer krankheit, die auf der gegenwart des anti-endothelin-antikörpers beruht
ATE454630T1 (de) 2006-08-04 2010-01-15 Celltrend Gmbh Verfahren zur diagnose einer erkrankung mit beteiligung eines anti-at1-rezeptor-antikörpers
BR112012026006A2 (pt) 2010-04-12 2019-09-24 Cell Trend GmbH método para diagnose de esclerose múltipla envolvendo anticorpo antirreceptor at1
US8483415B2 (en) 2010-06-18 2013-07-09 Motorola Mobility Llc Antenna system with parasitic element for hearing aid compliant electromagnetic emission
US20170082619A1 (en) 2015-09-23 2017-03-23 One Lambda, Inc. Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens
US10648977B2 (en) 2015-10-30 2020-05-12 The Johns Hopkins University Angiotensin receptor autoantibodies as biomarker for effected usage of angiotensin receptor blockers
WO2017123550A1 (en) * 2016-01-11 2017-07-20 Autotelic Llc Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
CN108948183B (zh) * 2018-06-05 2022-01-28 武汉华纪元生物技术开发有限公司 α1受体和AT1受体抗原类似物多肽及其抗体检测试剂盒和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2866182B2 (ja) 1990-10-08 1999-03-08 日本ケミファ株式会社 エンドセリン受容体
FR2787330A1 (fr) 1998-12-18 2000-06-23 Sanofi Sa Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe
DE19954305A1 (de) * 1998-12-24 2000-06-29 Max Delbrueck Centrum Peptide des AT¶1¶-Rezeptors und ihre Verwendung, insbesondere für die Diagnostider Präeklampsie
CA2363999A1 (en) 1998-12-24 2000-07-06 Max-Delbruck-Centrum Fur Molekulare Medizin Peptides of the at1 receptor and their use for preeclampsia and malign hypertension
CA2314811A1 (en) * 2000-08-02 2002-02-02 Brian Archibald Macvicar Autoimmunity to angiotensin at1 receptors in schizophrenia
DE10123929A1 (de) 2001-05-11 2002-11-21 Celltrend Gmbh Verfahren zur Vorhersage eines Transplantatabstoßungsrisikos und immunologischer Testkit
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
AU2003293004A1 (en) 2002-11-29 2004-06-23 Max-Delbruck-Centrum Fur Molekulare Medizin Identification of agonistic autoantibodies
US20060135422A1 (en) 2003-04-17 2006-06-22 Moskowitz David W Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE
WO2006060336A2 (en) 2004-11-30 2006-06-08 The Johns Hopkins University Endothelin-2 and retinal damage
EP1884776A1 (de) 2006-08-04 2008-02-06 Celltrend GmbH Verfahren zur diagnose einer krankheit, die auf der gegenwart des anti-endothelin-antikörpers beruht
ATE454630T1 (de) 2006-08-04 2010-01-15 Celltrend Gmbh Verfahren zur diagnose einer erkrankung mit beteiligung eines anti-at1-rezeptor-antikörpers

Also Published As

Publication number Publication date
US20100098688A1 (en) 2010-04-22
EP2057467A2 (de) 2009-05-13
ATE454630T1 (de) 2010-01-15
WO2008015218A2 (en) 2008-02-07
US8425877B2 (en) 2013-04-23
WO2008015218A3 (en) 2008-07-03
EP1884775B1 (de) 2010-01-06
ATE518139T1 (de) 2011-08-15
PL2057467T3 (pl) 2011-12-30
EP2057467B1 (de) 2011-07-27
EP1884775A1 (de) 2008-02-06
DE602006011602D1 (de) 2010-02-25
ES2336350T3 (es) 2010-04-12
ES2369798T3 (es) 2011-12-07

Similar Documents

Publication Publication Date Title
PL2057467T3 (pl) Sposób diagnozowania choroby z udziałem przeciwciała przeciwko receptorowi AT1
WO2010091049A3 (en) Diagnosis and treatment of cancer
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
MX382244B (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
EP3761034A3 (de) Urinbiomarker zur vorhersage der erholung nach einer akuten nierenverletzung: proteomik
EP1810026A4 (de) B7-h1 und verfahren zur diagnose, prognose und behandlung von krebs
EP3708682A3 (de) Verwendung von mikrovesikeln bei der diagnose und prognose von medizinischen krankheiten und leiden
EP1930426A4 (de) Zusammensetzung und verfahren zur diagnose von nierenkrebs und abschätzung der prognose eines nierenkrebspatienten
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
WO2012040073A3 (en) Biomarkers of renal injury
EP2069768A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes
WO2011107481A3 (en) Method of diagnostic of inflammatory bowel diseases
AR086734A1 (es) Metodos de diagnostico de la enfermedad tromboembolica
EP1960016A4 (de) Verfahren zur extrakorporalen entfernung einer pathogenen mikrobe, entzündungszelle oder eines entzündungsproteins aus blut
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
WO2010047938A3 (en) Mmp activation peptide detection in biological samples
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease
ATE528651T1 (de) Diagnoseverfahren für pulmonale arterielle hypertonie
WO2013048174A3 (ko) Ｃａ19-9, 카텝신 ｄ 및 매트릭스 메탈로프로틴나제-7의 측정수단을 포함하는 췌장암 진단용 키트
DE502006008028D1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina